Deciphering the molecular mechanisms of selective non-covalency demonstrated differentially by 9-Allylnaphtho[1,8-ef]isoindole-7,8,10(9H)-trione (C11) against fibroblast growth factor receptors 1–4

References

• Acevedo, V. D., Ittmann, M., & Spencer, D. M. (2009). Cell Cycle.
   PubMedGoogle Scholar
• Angevin, E., Lopez-Martin, J. A., Lin, C. C., Gschwend, J. E., Harzstark, A., Castellano, D., Soria, J. C., Sen, P., Chang, J., Shi, M., Kay, A. & Escudier, B. (2013). Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma. Clinical Cancer Research, https://doi.org/10.1158/1078-0432.CCR-12-2885
   Google Scholar
• Axon, C. (2020). Marvin version 20.19.3, ChemAxon. https://www.chemaxon.com
   Google Scholar
• Babina, I. S., & Turner, N. C. (2017). Advances and challenges in targeting FGFR signalling in cancer. Nature Reviews Cancer,  17(5), 318-332. https://doi.org/10.1038/nrc.2017.8
   Google Scholar
• Bello, E., Colella, G., Scarlato, V., Oliva, P., Berndt, A., Valbusa, G., Serra, S. C., D’Incalci, M., Cavalletti, E., Giavazzi, R., Damia, G. & Camboni, G. (2011). E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Research, https://doi.org/10.1158/0008-5472.CAN-10-2700
   Google Scholar
• Berendsen, H. J. C., Postma, J. P. M., Van Gunsteren, W. F., Dinola, A., Haak, J. R., Berendsen, H. J. C., Postma, J. P. M., Van Gunsteren, W. F., Dinola, A., & Haak, J. R. (1984). Molecular dynamics with coupling to an external bath molecular dynamics with coupling to an external bath. Journal of Chemical Physics, 81(8), 3684–3935. https://doi.org/10.1063/1.448118
   Google Scholar
• Brameld, K. A., Owens, T. D., Verner, E., Venetsanakos, E., Bradshaw, J. M., Phan, V. T., Tam, D., Leung, K., Shu, J., LaStant, J., Loughhead, D. G., Ton, T., Karr, D. E., Gerritsen, M. E., Goldstein, D. M., & Funk, J. O. (2017). Acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (PRN1371) for the Treatment of Solid Tumors. Journal of Medicinal Chemistry, 60(15), 6516–6527. acs.jmedchem. https://doi.org/10.1021/acs.jmedchem.7b00360
   PubMed Web of Science ®Google Scholar
• Case, D. A. (2018). Amber 18. San Fr: Univ. California.
   Google Scholar
• Chen, Z., Jiang Tong, L., You Tang, B., Yan Liu, H., Wang, X., Zhang, T., Wen Cao, X., Chen, Y., Lin Li, H., Hong Qian, X., Fang Xu, Y., Xie, H., & Ding, J. (2018). C11, a novel fibroblast growth factor receptor 1 (FGFR1) inhibitor, suppresses breast cancer metastasis and angiogenesis. Acta Pharmacologica Sinica, https://doi.org/10.1038/s41401-018-0191-7
   Google Scholar
• Chen, Z., Wang, X., Zhu, W., Cao, X., Tong, L., Li, H., Xie, H., Xu, Y., Tan, S., Kuang, D., Ding, J., & Qian, X. (2011). Acenaphtho[1,2-b]pyrrole-based selective fibroblast growth factor receptors 1 (FGFR1) inhibitors: Design, synthesis, and biological activity. Journal of Medicinal Chemistry, https://doi.org/10.1021/jm200258t
   Google Scholar
• Dai, S., Zhou, Z., Chen, Z., Xu, G., & Chen, Y. (2019). Fibroblast growth factor receptors (FGFRs): Structures and small molecule inhibitors. Cells, https://doi.org/10.3390/cells8060614
   Google Scholar
• Ebiike, H., Taka, N., Matsushita, M., Ohmori, M., Takami, K., Hyohdoh, I., Kohchi, M., Hayase, T., Nishii, H., Morikami, K., Nakanishi, Y., Akiyama, N., Shindoh, H., Ishii, N., Isobe, T., & Matsuoka, H. (2016). Discovery of [5-amino-1-(2-methyl-3H-benzimidazol-5-yl)pyrazol-4-yl]-(1H-indol-2-yl)methanone (CH5183284/Debio 1347). An orally available and selective fibroblast growth factor receptor (FGFR) inhibitor. Journal of Medicinal Chemistry, https://doi.org/10.1021/acs.jmedchem.6b01156.
   Google Scholar
• Farrell, B., & Breeze, A. L. (2018). Biochemical Society Transactions.
   PubMedGoogle Scholar
• Frisch, M. J. G., Trucks, W., Schlegel, H. B., Scuseria, G. E., Robb, M. A., Cheeseman, J. R., Scalmani, G., Barone, V., Mennucci, B., Petersson, G. A., Nakatsuji, H., Caricato, M., Li, X., Hratchian, H. P., Izmaylov, A. F., Bloino, J., Zheng, G., & Sonnenberg, J. L. (2016). Gaussian, 16.
   Google Scholar
• Fu, W., Chen, L., Wang, Z., Kang, Y., Wu, C., Xia, Q., Liu, Z., Zhou, J., Liang G., & Cai, Y. (2017). Theoretical studies on FGFR isoform selectivity of FGFR1/FGFR4 inhibitors by molecular dynamics simulations and free energy calculations. Physical Chemistry Chemical Physics, https://doi.org/10.1039/c6cp07964d
   Google Scholar
• Fumarola, C., Bozza, N., Castelli, R., Ferlenghi, F., Marseglia, G., Lodola, A., Bonelli, M., La Monica, S., Cretella, D., Alfieri, R., Minari, R., Galetti, M., Tiseo, M., Ardizzoni, A., Mor, M., & Petronini, P. G. (2019). Expanding the arsenal of FGFR inhibitors: A novel chloroacetamide derivative as a new irreversible agent with anti-proliferative activity against FGFR1-amplified lung cancer cell lines. Frontiers in Oncology, 9, 179. DOI:10.3389/fonc.2019.00179.
   PubMed Web of Science ®Google Scholar
• Gavine, P. R., Mooney, L., Kilgour, E., Thomas, A. P., Al-Kadhimi, K., Beck, S., Rooney, C., Coleman, T., Baker, D., Mellor, M. J., Brooks, A. N., & Klinowska, T. (2012). AZD4547: An orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Research, https://doi.org/10.1158/0008-5472.CAN-11-3034
   Google Scholar
• Gozgit, J. M., Wong, M. J., Moran, L., Wardwell, S., Mohemmad, Q. K., Narasimhan, N. I., Shakespeare, W. C., Wang, F., Clackson, T., & Rivera, V. M. (2012). Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models. Molecular Cancer Therapeutics, https://doi.org/10.1158/1535-7163.MCT-11-0450
   Google Scholar
• Guagnano, V., Kauffmann, A., Wöhrle, S., Stamm, C., Ito, M., Barys, L., Pornon, A., Yao, Y., Li, F., Zhang, Y., Chen, Z., Wilson, C. J., Bordas, V., Le Douget, M., Alex Gaither, L., Borawski, J., Monahan, J. E., Venkatesan, K., Brümmendorf, T., Thomas, D. M. … Graus-Porta, D., et al. (2012). FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective Pan-FGFR inhibitor. Cancer Discovery, https://doi.org/10.1158/2159-8290.CD-12-0210.
   Google Scholar
• Hallinan, N., Finn, S., Cuffe, S., Rafee, S., O’Byrne K., & Gately K. (2016). Cancer Treatment Reviews.
   PubMedGoogle Scholar
• Heist, R. S., Mino-Kenudson, M., Sequist, L. V., Tammireddy, S., Morrissey, L., Christiani, D. C., Engelman, J. A., & Iafrate, A. J. (2012). FGFR1 amplification in squamous cell carcinoma of the lung. Journal of Thoracic Oncology, https://doi.org/10.1097/JTO.0b013e31826aed28
   Google Scholar
• Hess, B., Bekker, H., Berendsen, H. J. C., & Fraaije, J. G. E. M. (1997). LINCS: A linear constraint solver for molecular simulations. Journal of Computational Chemistry, 18(12), 1463–1472. https://doi.org/10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H
   Web of Science ®Google Scholar
• Hilberg, F., Roth, G. J., Krssak, M., Kautschitsch, S., Sommergruber, W., Tontsch-Grunt, U., Garin-Chesa, P., Bader, G., Zoephel, A., Quant, J., Heckel, A., & Rettig, W. J. (2008). BIBF 1120: Triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Research, https://doi.org/10.1158/0008-5472.CAN-07-6307
   Google Scholar
• Katoh, M. (2019). Nature Reviews Clinical Oncology.
   Google Scholar
• Kuriwaki, I., Kameda, M., Hisamichi, H., Kikuchi, S., Iikubo, K., Kawamoto, Y., Moritomo, H., Kondoh, Y., Amano, Y., Tateishi, Y., Echizen, Y., Iwai, Y., Noda, A., Tomiyama, H., Suzuki, T. & Hirano, M. (2020). Structure-based drug design of 1,3,5-triazine and pyrimidine derivatives as novel FGFR3 inhibitors with high selectivity over VEGFR2. Bioorganic & Medicinal Chemistry, https://doi.org/10.1016/j.bmc.2020.115453
   Google Scholar
• Lee, H. J., Seo, A. N., Park, S. Y., Kim, J. Y., Park, J. Y., Yu, J. H., Ahn, J. H., & Gong, G. (2014). Low prognostic implication of fibroblast growth factor family activation in triple-negative breast cancer subsets. Annals of Surgical Oncology, https://doi.org/10.1245/s10434-013-3456-x
   Google Scholar
• Lin, X., Yosaatmadja, Y., Kalyukina, M., Middleditch, M. J., Zhang, Z., Lu, X., Ding, K., Patterson, A. V., Smaill, J. B., & Squire, C. J. (2019). Rotational freedom, steric hindrance, and protein dynamics explain BLU554 selectivity for the hinge cysteine of FGFR4. ACS Medicinal Chemistry Letters, https://doi.org/10.1021/acsmedchemlett.9b00196.
   Google Scholar
• Lobanov, M. Y., Bogatyreva, N. S., & Galzitskaya, O. V. (2008). Radius of gyration as an indicator of protein structure compactness. Molecular Biology, 42(4), 623–628. https://doi.org/10.1134/S0026893308040195
   Web of Science ®Google Scholar
• M., Peifer, L., Fernández-Cuesta, M. L., Sos, J., George, D., Seidel, L. H., Kasper, D., Plenker, F., Leenders, R., Sun, T., Zander, R., Menon, M., Koker, I., Dahmen, C., Müller, V. D., Cerbo, H. U., Schildhaus, J., Altmüller, I., Baessmann, C., Becker, … Lantuejoul, P., et al. (2012). Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nature Genetics, https://doi.org/10.1038/ng.2396
   Google Scholar
• Mohammadi, M., Schlessinger, J., & Hubbard, S. R. (1996). Structure of the FGF receptor tyrosine kinase domain reveals a novel autoinhibitory mechanism. Cell, https://doi.org/10.1016/S0092-8674(00)80131-2.
   Google Scholar
• Ornitz, D., & Itoh, M. N. (2015). The fibroblast growth factor signaling pathway. Wiley Interdisciplinary Reviews: Developmental Biology, https://doi.org/10.1002/wdev.176.
   Google Scholar
• Pan, Y. L., Liu, Y. L., & Chen, J. Z. (2018). Computational simulation studies on the binding selectivity of 1-(1H-benzimidazol-5-yl)-5-aminopyrazoles in complexes with FGFR1 and FGFR4. Molecules, https://doi.org/10.3390/molecules23040767.
   Google Scholar
• Patani, H., Bunney, T. D., Thiyagarajan, N., Norman, R. A., Ogg, D., Breed, J., Ashford, P., Potterton, A., Edwards, M., Williams, S. V., Thomson, G. S., Pang, C. S. M., Knowles, M. A., Breeze, A. L., Orengo, C., Phillips, C., &Katan, M. (2016). Landscape of activating cancer mutations in FGFR kinases and their differential responses to inhibitors in clinical use. Oncotarget, https://doi.org/10.18632/oncotarget.8132
   Google Scholar
• Perera, T. P. S., Jovcheva, E., Mevellec, L., Vialard, J., De Lange, D., Verhulst, T., Paulussen, C., Van De Ven, K., King, P., Freyne, E., Rees, D. C., Squires, M., Saxty, G., Page, M., Murray, C. W., Gilissen, R., Ward, G., Thompson, N. T. Newell, D. R. … Lorenzi, M. V., et al. (2017). Discovery & pharmacological characterization of JNJ-42756493 (Erdafitinib), a functionally selective small-molecule FGFR family inhibitor. Molecular Cancer Therapeutics, https://doi.org/10.1158/1535-7163.MCT-16-0589
   Google Scholar
• Perez-Garcia, J., Muñoz-Couselo, E., Soberino, J., Racca, F. & Cortes, J. (2018). Targeting FGFR pathway in breast cancer. Breast, https://doi.org/10.1016/j.breast.2017.10.014.
   Google Scholar
• Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. C., & Ferrin, T. E. (2004). UCSF Chimera – A visualization system for exploratory research and analysis. Journal of Computational Chemistry, 25(13), 1605–1612. https://doi.org/10.1002/jcc.20084
   PubMed Web of Science ®Google Scholar
• Porta, R., Borea, R., Coelho, A., Khan, S., Araújo, A., Reclusa, P., Franchina, T., Van Der Steen, N., Van Dam, P., Ferri, J., Sirera, R., Naing, A., Hong D., & Rolfo, C. (2017). Critical Reviews in Oncology Hematology.
   PubMedGoogle Scholar
• Reis-Filho, J. S., Simpson, P. T., Turner, N. C., Lambros, M. B., Jones, C., Mackay, A., Grigoriadis, A., Sarrio, D., Savage, K., Dexter, T., Iravani, M., Fenwick, K., Weber, B., Hardisson, D., Schmitt, F. C., Palacios, J., Lakhani, S. R., & Ashworth, A. (2006). FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas. Clin. Cancer Res, https://doi.org/10.1158/1078-0432.CCR-06-1164
   Google Scholar
• Seifert, E. (2014). OriginPro 9.1: Scientific data analysis and graphing software––Software review. Journal of Chemical Information and Modeling, 54(5), 1552–1552. https://doi.org/10.1021/ci500161d
   PubMed Web of Science ®Google Scholar
• Sittel, F., Jain, A., & Stock, G. (2014). Principal component analysis of molecular dynamics: On the use of Cartesian vs. internal coordinates. Journal of Chemical Physics, https://doi.org/10.1063/1.4885338
   Google Scholar
• Sohl, C. D., Ryan, M. R., Luo, B., Frey, K. M., & Anderson, K. S. (2015). Illuminating the molecular, mechanisms of tyrosine kinase inhibitor resistance for the FGFR1 gatekeeper mutation: The Achilles’ heel of targeted therapy. ACS Chemical Biology, https://doi.org/10.1021/acschembio.5b00014.
   Google Scholar
• Tiseo, M., Gelsomino, F., Alfieri, R., Cavazzoni, A., Bozzetti, C., De Giorgi, A. M., Petronini, P. G., & Ardizzoni, A. (2015). Cancer Treatment Reviews.
   PubMedGoogle Scholar
• Touat, M., Ileana, E., Postel-Vinay, S., André, F., & Soria, J. C. (2015). Targeting FGFR signaling in cancer. Clinical Cancer Research, https://doi.org/10.1158/1078-0432.CCR-14-2329
   Google Scholar
• Tucker, J. A., Klein, T., Breed, J., Breeze, A. L., Overman, R., Phillips, C., & Norman, R. A. (2014). Structural insights into FGFR kinase isoform selectivity: Diverse binding modes of AZD4547 and ponatinib in complex with FGFR1 and FGFR4. Structure, https://doi.org/10.1016/j.str.2014.09.019
   Google Scholar
• Turner, N., & Grose, R. (2010). Nature Reviews Cancer.
   PubMedGoogle Scholar
• Venetsanakos, E., Brameld, K. A., Phan, V. T., Verner, E., Owens, T. D., Xing, Y., Tam, D., LaStant, J., Leung, K., Karr, D. E., Hill, R. J., Gerritsen, M. E., Goldstein, D. M., Funk, J. O., & Bradshaw, J. M. (2017). The irreversible covalent fibroblast growth factor receptor inhibitor PRN1371 exhibits sustained inhibition of FGFR after drug clearance. Molecular Cancer Therapeutics, https://doi.org/10.1158/1535-7163.MCT-17-0309
   Google Scholar
• Weiss, J., Sos, M. L., Seidel, D., Peifer, M., Zander, T., Heuckmann, J. M., Ullrich, R. T., Menon, R., Maier, S., Soltermann, A., Moch, H., Wagener, P., Fischer, F., Heynck, S., Koker, M., Schöttle, J., Leenders, F., Gabler, F. Dabow, I. … Thomas, R. K., et al. (2010). Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Science Translational Medicine, https://doi.org/10.1126/scitranslmed.3001451.
   Google Scholar
• Wolf, A., & Kirschner, K. N. (2013). Principal component and clustering analysis on molecular dynamics data of the ribosomal L11·23S subdomain. Journal of Molecular Modeling, 19(2), 539–549. https://doi.org/10.1007/s00894-012-1563-4
   PubMed Web of Science ®Google Scholar
• Yeung, K. T., & Cohen, E. E. W. (2015). Lenvatinib in Advanced, Radioactive Iodine-Refractory, Differentiated Thyroid Carcinoma. Clinical Cancer Research, https://doi.org/10.1158/1078-0432.CCR-15-0923
   Google Scholar
• Zhao, G., Li, W. Y., Chen, D., Henry, J. R., Li, H. Y., Chen, Z., Zia-Ebrahimi, M., Bloem, L., Zhai, Y., Huss, K., Bin Peng, S., & McCann, D. J. (2011). A novel, selective inhibitor of fibroblast growth factor receptors that shows a potent broad spectrum of antitumor activity in several tumor xenograft models. Molecular Cancer Therapeutics, https://doi.org/10.1158/1535-7163.MCT-11-0306
   Google Scholar